Dramatic cessation of gross sustained treatment resistant hematuria after [177Lu]Lu-PSMA-617 therapy: A case report

Document Type : Case Report


1 Kidney Transplant Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2 Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran



We report a patient with locally invasive metastatic castration resistant prostate adenocarcinoma, which had massive invasion to the bladder and caused frequent gross hematuria. The patient had received more than 10 units of packed cell at the time he was referred for [177Lu]Lu-PSMA-617 therapy, but despite frequent transfusions his serum hemoglobin level had been under 8 g/dl most of the time. He had received first generation androgen deprivation therapy (ADT) from 3 years previously and the second generation since 1 year ago and had undergone multiple procedures for cessation of hematuria, such as multiple cystoscopies, bladder irrigations and angioembolizations. We performed [99mTc]Tc-PSMA whole body and SPECT/CT scan, which demonstrated a large PSMA avid prostate mass invading the urinary bladder wall. All components of the locally invasive tumor were present demonstrating high PSMA avidity, so he was scheduled for [177Lu]Lu-PSMA-617 therapy. One week after the diagnostic scan, therapeutic dose of [177Lu]Lu-PSMA-617 was administered. The patient reported no hematuria 4 days after the [177Lu]Lu-PSMA-617 administration. In the follow up, no recurrent hematuria was reported, too. The PSA level also declined from 40.5 ng/ml to 18.7 ng/ml, 1 month after the first treatment.


Main Subjects

  1. Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Kumar AR, Murphy DG, Eu P, Jackson P , Scalzo M, Williams  SG, Sandhu S. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018 Jun;19(6):825-833.
  2. Rahbar K, Bodei L, Morris MJ. Is the vision of radioligand therapy for prostate cancer becoming a reality? An overview of the phase III VISION trial and its importance for the future of theranostics. J Nucl Med. 2019 Nov;60(11):1504-1506.
  3. Kabasakal L, Toklu T, Yeyin N, Demirci E, Abuqbeitah M, Ocak M, Aygün A, Karayel E, Pehlivano─člu H, Selçuk NA. Lu-177-PSMA-617 prostate-specific membrane antigen inhibitor therapy in patients with castration-resistant prostate cancer: stability, bio-distribution and dosimetry. Mol Imaging Radionucl Ther. 2017 Jun 1;26(2):62-68.
  4. Hofman MS, Emmett L, Violet J, Zhang AY, Lawrence NJ, Stockler M, Francis RJ, Iravani A, Williams S, Azad A, Martin A, McJannett M, Davis ID. TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU Int. 2019 Nov;124 Suppl 1:5-13.